DATE

Partnering to address the rising cost of clinical trials

The cost of the clinical trial process today is upwards of $100mn. So how can drug developers with robust R&D pipelines but a limited operating budget make the most of their portfolios and get as many promising new therapies to market in the narrow window before patents expire?

In a word, partnerships. In this article, Ben van der Schaaf at Arthur D. Little discusses why by working with CROs, universities, and patient advocacy organizations, innovative drug makers can find investors who see their intellectual property as a valuable starting point for the drug development process.

Partnering to address the rising cost of clinical trials

DATE

The cost of the clinical trial process today is upwards of $100mn. So how can drug developers with robust R&D pipelines but a limited operating budget make the most of their portfolios and get as many promising new therapies to market in the narrow window before patents expire?

In a word, partnerships. In this article, Ben van der Schaaf at Arthur D. Little discusses why by working with CROs, universities, and patient advocacy organizations, innovative drug makers can find investors who see their intellectual property as a valuable starting point for the drug development process.